Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cancer

Cancer

Telomeric repeat binding factor 2 (TERF2)

Mouse and patient sample studies suggest inhibiting TERF2 could help treat cancer by promoting the recruitment of NK cells. In immunocompromised mice injected with transformed fibroblasts with Terf2 knockdown, depleting NK cells led to increased tumor formation compared with no depletion. In samples from patients with colon cancer, decreased expression of TERF2 correlated with increased NK cell density during cancer progression. Next steps include screening for compounds that specifically prevent the TERF2-mediated inhibition of NK cells.

SciBX 6(30); doi:10.1038/scibx.2013.786
Published online Aug. 8, 2013

Unpatented; unavailable for licensing

Biroccio, A. et al. Nat. Cell Biol.; published online June 23, 2013;
doi:10.1038/ncb2774
Contact: Eric Gilson, Normal Superior School of Lyon, Lyon, France
e-mail:
eric.gilson@unice.fr
Contact: Annamaria Biroccio,
same affiliation as above
e-mail:
biroccio@ifo.it